US 9,416,157

Application 13/360,163 · Granted Aug 16, 2016

Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity

Estimated expiration

December 11, 2026

20 days remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
  • Could not fetch continuity data for application PCTCA2006001650: Resource not found (404)
Earliest effective filing
Oct 4, 2006
+ 20 years
Oct 4, 2026
PTA +906d
Mar 28, 2029
TD cap (US 8,791,061)
Dec 11, 2026
Final
Dec 11, 2026

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
January 27, 2012
Earliest effective filing
October 4, 2006
Issue date
August 16, 2016
PTA
+906 days
Base expiry (before PTA)
October 4, 2026

October 4, 2006 + 20 years = October 4, 2026 + 906 PTA days = March 28, 2029

  • Continuation of application 12/083,086, filed Apr 4, 2008, issued as US 8,124,721
  • National stage entry of application PCTCA2006001650, filed Oct 4, 2006
  • National stage entry of application PCTCA2006001650, filed Oct 4, 2006
  • PRO60/722,962 — Provisional — not used for base term
  • PRO60/722,958 — Provisional — not used for base term
  • PRO60/722,959 — Provisional — not used for base term
  • PRO60/722,962 — Provisional — not used for base term
  • PRO60/722,958 — Provisional — not used for base term
  • PRO60/722,959 — Provisional — not used for base term

Terminal disclaimers

TD approved2 approved, 3 filed

TD caps expiration to December 11, 2026 (earliest expiring referenced patent: US 8,791,061)

  • US 8,124,721· Application 12/083,086Capping patent

    Peptides for modulating innate immunity

    Filing date
    Apr 4, 2008
    Earliest effective filing
    Oct 4, 2006
    Issue date
    Feb 28, 2012
    PTA
    +546 days
    Calculated expiration
    Apr 2, 2028

    National stage entry of PCTCA2006001650, filed Oct 4, 2006

    Oct 4, 2006 + 20y + 546d PTA = Apr 2, 2028

  • US 9,416,157· Application 13/360,163(from application 13/360,163)

    Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity

    Filing date
    Jan 27, 2012
    Earliest effective filing
    Oct 4, 2006
    Issue date
    Aug 16, 2016
    PTA
    +906 days
    Calculated expiration
    Mar 28, 2029

    Continuation of 12/083,086, filed Apr 4, 2008, issued as US 8,124,721

    National stage entry of PCTCA2006001650, filed Oct 4, 2006

    National stage entry of PCTCA2006001650, filed Oct 4, 2006

    Oct 4, 2006 + 20y + 906d PTA = Mar 28, 2029

  • US 8,791,061· Application 13/457,162Capping patent

    Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity

    Filing date
    Apr 26, 2012
    Earliest effective filing
    Oct 4, 2006
    Issue date
    Jul 29, 2014
    PTA
    +68 days
    Calculated expiration
    Dec 11, 2026

    Continuation of 12/404,965, filed Mar 16, 2009

    Continuation of 11/730,695, filed Apr 3, 2007

    Continuation of 11/730,695, filed Apr 3, 2007

    Continuation-in-part of 13/360,163, filed Jan 27, 2012, issued as US 9,416,157

    Continuation of 12/083,086, filed Apr 4, 2008, issued as US 8,124,721

    National stage entry of PCTCA2006001650, filed Oct 4, 2006

    National stage entry of PCTCA2006001650, filed Oct 4, 2006

    Continuation of 12/083,086, filed Apr 4, 2008, issued as US 8,124,721

    National stage entry of PCTCA2006001650, filed Oct 4, 2006

    Oct 4, 2006 + 20y + 68d PTA = Dec 11, 2026

  • US 8,791,061· Application 13/457,162(from application 13/457,162)

    Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity

    Filing date
    Apr 26, 2012
    Earliest effective filing
    Oct 4, 2006
    Issue date
    Jul 29, 2014
    PTA
    +68 days
    Calculated expiration
    Dec 11, 2026

    Continuation of 12/404,965, filed Mar 16, 2009

    Continuation of 11/730,695, filed Apr 3, 2007

    Continuation of 11/730,695, filed Apr 3, 2007

    Continuation-in-part of 13/360,163, filed Jan 27, 2012, issued as US 9,416,157

    Continuation of 12/083,086, filed Apr 4, 2008, issued as US 8,124,721

    National stage entry of PCTCA2006001650, filed Oct 4, 2006

    National stage entry of PCTCA2006001650, filed Oct 4, 2006

    Continuation of 12/083,086, filed Apr 4, 2008, issued as US 8,124,721

    National stage entry of PCTCA2006001650, filed Oct 4, 2006

    Oct 4, 2006 + 20y + 68d PTA = Dec 11, 2026

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 13/360,163 · US 9,416,157

PatentReply compiles the prosecution history behind US 9,416,157: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US9416157

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.